Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
Status:
Terminated
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
This study will test the safety, tolerance, and efficacy of different doses of oral gallium
maltolate. Patients will receive oral gallium maltolate twice daily for 28-consecutive days
followed by 14 days off treatment. This dosing cycle will be repeated. Adverse effects will
be assessed and the levels of gallium in serum will be measured. Any effect of the drug on
the cancer and any improvement in cancer-related symptoms will also be measured.